None
THOUSAND OAKS, Calif. , Dec. 2, 2024 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at Citi's 2024 Global Healthcare Conference at 9:30 a.m. ET on Thursday , Dec. 5, 2024. Peter Griffith , executive vice president and chief financial officer at Amgen, Jay Bradner , executive vice president of Research and Development and chief scientific officer at Amgen, and Susan Sweeney , executive vice president of Obesity and Related Conditions at Amgen, will participate in a fireside chat at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public. The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com , under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event. About Amgen Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions . Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average ® , and it is also part of the Nasdaq-100 Index ® , which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average and is also part of the Nasdaq-100 index. In 2023, Amgen was named one of "America's Greatest Workplaces" by Newsweek, one of "America's Climate Leaders" by USA Today and one of the "World's Best Companies" by TIME. For more information, visit Amgen.com and follow us on X (formerly known as Twitter), LinkedIn , Instagram , TikTok , YouTube and Threads . Amgen Forward-Looking Statements This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla ® (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), our acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, any potential strategic benefits, synergies or opportunities expected as a result of such acquisition, and any projected impacts from the Horizon acquisition on our acquisition-related expenses going forward), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on our business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico , and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful. There can be no guarantee that we will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. We may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of our information technology systems could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business and operations may be negatively affected by the failure, or perceived failure, of achieving our environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect our business and operations. Global economic conditions may magnify certain risks that affect our business. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all. CONTACT: Amgen, Thousand Oaks Elissa Snook , 609-251-1407 (media) Justin Claeys , 805-313-9775 (investors) SOURCE AmgenSAN RAMON, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, today announced financial results for its fiscal fourth quarter and full year ended October 31, 2024. Fourth quarter 2024 revenue of $1,018.4 million, up 10%, or up 7% organically. Fiscal year 2024 revenue of $3.9 billion, up 8%, or up 8% organically. Fourth quarter 2024 GAAP diluted earnings per share (EPS) of $0.58, up 38%. Fiscal 2024 GAAP diluted EPS of $1.96, up 33%. Fourth quarter 2024 non-GAAP diluted EPS of $1.04, up 19%. Fiscal 2024 non-GAAP diluted EPS of $3.69, up 15%. See "Reconciliation of Selected GAAP Results to Non-GAAP Results" below. Commenting on the results, Al White, Cooper's President and CEO said, "Fiscal 2024 was a great year for Cooper having achieved record consolidated revenues, including record CooperVision revenues, record CooperSurgical revenues and record non-GAAP EPS. We look forward to continued success in fiscal 2025 and thank all of our employees for driving these results." Fourth Quarter Operating Results Revenue of $1,018.4 million, up 10% from last year’s fourth quarter, up 9% in constant currency, up 7% organically. Gross margin of 67% compared with 65% in last year’s fourth quarter driven by price and efficiency gains. On a non-GAAP basis, gross margin was similar to last year at 67%. Operating margin of 19% compared with 15% in last year’s fourth quarter driven by SG&A expense leverage and stronger gross margins. On a non-GAAP basis, operating margin was 26%, up from 24% last year. Interest expense of $27.0 million compared with $26.3 million in last year's fourth quarter. On a non-GAAP basis, interest expense was $25.6 million, down from $26.4 million. Cash provided by operations of $268.1 million offset by capital expenditures of $139.9 million resulted in free cash flow of $128.2 million. Fourth Quarter CooperVision (CVI) Revenue Revenue of $676.4 million, up 9% from last year’s fourth quarter, up 8% in constant currency, up 8% organically. Revenue by category: Revenue by geography: Fourth Quarter CooperSurgical (CSI) Revenue Revenue of $342.0 million, up 12% from last year's fourth quarter, up 12% in constant currency, up 5% organically. Revenue by category: Fiscal Year 2024 Operating Results Revenue of $3,895.4 million, up 8% from fiscal 2023, up 9% in constant currency, up 8% organically. CVI revenue of $2,609.4 million, up 8% from fiscal 2023, up 8% in constant currency, up 9% organically, and CSI revenue $1,286.0 million, up 10% from fiscal 2023, up 11% in constant currency, up 5% organically. Gross margin of 67% compared with 66% in fiscal 2023. Non-GAAP gross margin was 67% compared with 66% in fiscal 2023. Operating margin of 18% compared with 15% in fiscal 2023. Non-GAAP operating margin was 25% compared with 24% in fiscal 2023. Cash provided by operations of $709.3 million offset by capital expenditures of $421.2 million resulted in free cash flow of $288.1 million. Fiscal Year 2025 Financial Guidance The Company initiated its fiscal year 2025 financial guidance. Details are summarized as follows: Fiscal 2025 total revenue of $4,080 - $4,158 million (organic growth of 6% to 8%) CVI revenue of $2,733 - $2,786 million (organic growth of 6.5% to 8.5%) CSI revenue of $1,347 - $1,372 million (organic growth of 4% to 6%) Fiscal 2025 non-GAAP diluted earnings per share of $3.92 - $4.02 Non-GAAP diluted earnings per share guidance excludes amortization and impairment of intangible assets, and certain income or gains and charges or expenses including acquisition and integration costs which we may incur as part of our continuing operations. With respect to the Company’s guidance expectations, the Company has not reconciled non-GAAP diluted earnings per share guidance to GAAP diluted earnings per share due to the inherent difficulty in forecasting acquisition-related, integration and restructuring charges and expenses, which are reconciling items between the non-GAAP and GAAP measures. Due to the unknown effect, timing and potential significance of such charges and expenses that impact GAAP diluted earnings per share, the Company is not able to provide such guidance. Reconciliation of Selected GAAP Results to Non-GAAP Results To supplement our financial results and guidance presented on a GAAP basis, we provide non-GAAP measures such as non-GAAP gross margin, non-GAAP operating margin, non-GAAP diluted earnings per share, as well as constant currency and organic revenue growth because we believe they are helpful for the investors to understand our consolidated operating results. Management uses supplemental non-GAAP financial measures internally to understand, manage and evaluate our business, to make operating decisions, and to plan and forecast for future periods. The non-GAAP measures exclude costs which we generally would not have otherwise incurred in the periods presented as a part of our continuing operations. We provide further details of the non-GAAP adjustments made to arrive at our non-GAAP measures in the GAAP to non-GAAP reconciliations below. Our non-GAAP financial results and guidance are not meant to be considered in isolation or as a substitute for comparable GAAP measures and should be read only in conjunction with our consolidated financial statements prepared in accordance with GAAP. To present constant currency revenue growth, current period revenue for entities reporting in currencies other than the United States dollar are converted into United States dollars at the average foreign exchange rates for the corresponding period in the prior year. To present organic revenue growth, we excluded the effect of foreign currency fluctuations and the impact of any acquisitions, divestitures and discontinuations that occurred in the comparable period. We define the non-GAAP measure of free cash flow as cash provided by operating activities less capital expenditures. We believe free cash flow is useful for investors as an additional measure of liquidity because it represents cash that is available to grow the business, make strategic acquisitions, repay debt, or buyback common stock. Management uses free cash flow internally to understand, manage, make operating decisions and evaluate our business. In addition, we use free cash flow to help plan and forecast future periods. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP. EPS, amounts and percentages may not sum or recalculate due to rounding. (1) Charges include the direct effects of acquisition accounting, such as amortization of inventory fair value step-up, professional services fees, regulatory fees and changes in fair value of contingent considerations, and items related to integrating acquired businesses, such as redundant personnel costs for transitional employees, other acquired employee related costs, and integration-related professional services, manufacturing integration costs, legal entity rationalization and other integration-related activities. The acquisition and integration-related charges in fiscal 2024 were primarily related to the Cook Medical acquisition and integration expenses. The acquisition and integration-related charges in fiscal 2023 were primarily related to the Generate acquisition and integration expenses. Charges included $2.9 million and $8.4 million related to redundant personnel costs for transitional employees, $0.7 million and $4.5 million of professional services fees, $1.4 million and $1.4 million of manufacturing integration costs, $1.5 million and 1.5 million of inventory fair value step-up amortization, and $0.7 million and $4.1 million of other acquisition and integration-related activities in the three and twelve months ended October 31, 2024, respectively. The twelve months ended October 31, 2024 also included $0.7 million regulatory fees. Charges included $7.5 million and $21.9 million related to redundant personnel costs for transitional employees, $6.5 million and $16.2 million of professional services fees, $2.9 million and $6.5 million of manufacturing integration costs, $3.1 million and $5.0 million of legal entity rationalization costs, $0.9 million and $2.7 million regulatory fees, and $0.6 million and $5.0 million in other acquisition and integration-related activities, in the three and twelve months ended October 31, 2023, respectively. (2) Charges include costs related to product line exits such as inventory write-offs, site closure costs, contract termination costs and specifically-identified long-lived asset write-offs. Charges included $2.3 million of write-offs of long-lived assets and $1.7 million of other costs related to product line exits in the twelve months October 31, 2024. No charge related to product line exits was incurred in the three months ended October 31, 2024. Charges included $3.4 million and $7.9 million of site closure costs related to the exit of the lens care business, $0.4 million and $1.1 million of other costs related to product line exits in the three and twelve months ended October 31, 2023, respectively. The fourth quarter of fiscal 2023 also included $9.8 million of intangible assets impairment charge associated with the discontinuation of certain products. (3) Charges represent incremental costs of complying with the new European Union (E.U.) medical device regulations for previously registered products and primarily include charges for contractors supporting the project and other direct third-party expenses. We consider these costs to be limited to a specific time period. (4) Charges represent the costs associated with initiatives to increase efficiencies across the organization and optimize our overall cost structure, including changes to our IT infrastructure and operations, employee severance costs, legal entity and other business reorganizations, write-offs or impairments of certain long-lived assets associated with the business optimization activities. Charges included $1.5 million and $10.6 million of employee severance costs, $1.0 million and $4.1 million related to changes to our IT infrastructure and operation, and $0.4 million and $2.9 million of legal entity and other business reorganizations costs, in the three and twelve months ended October 31, 2024, respectively. The twelve months ended October 31, 2024 also included $0.7 million of other optimization costs. Charges included $1.4 million and $11.3 million of employee severance costs, $1.4 million and $1.9 million of legal entity and other business reorganizations costs, and $0.3 million and $5.9 million related to changes to our IT infrastructure and operations, partially offset by $0.2 million and $0.4 million of other items in the three and twelve months ended October 31, 2023, respectively. (5) Amount represents an accrual for probable payment of a termination fee in connection with an asset purchase agreement in the second quarter of 2023, which was paid in August 2023. (6) Amount represents the release the contingent consideration liability associated with SightGlass Vision's regulatory approval milestone in the first quarter of 2023. (7) Charges include certain business disruptions from natural causes, litigation matters and other items that are not part of ordinary operations. The adjustments to arrive at non-GAAP net income also include gains and losses on minority interest investments and accretion of interest attributable to acquisition installment payables. Charges included $1.5 million and $5.9 million of gains and losses on minority interest investments, $1.4 million and $5.5 million of accretion of interest attributable to acquisition installments payable, $0.6 million and $1.5 million related to legal matters in the three and twelve months ended October 31, 2024, respectively. Charges included $1.6 million and $6.3 million of gains and losses on minority interest investments, and $1.3 million and $4.6 million related to legal matters in the three and twelve months ended October 31, 2023, respectively. The twelve months ended October 31, 2023 also included $1.1 million of other items. (8) In fiscal 2021, the Company transferred its CooperVision intellectual property and goodwill to its UK subsidiary. As a result, we recorded a deferred tax asset equal to approximately $2.0 billion as a one-time tax benefit in accordance with U.S. GAAP in fiscal 2021 as subsequently adjusted for changes in UK tax law. The non-GAAP adjustments reflect the ongoing net deferred tax benefit from tax amortization each period under UK tax law. Audio Webcast and Conference Call The Company will host an audio webcast today for the public, investors, analysts and news media to discuss its fourth quarter results and current corporate developments. The audio webcast will be broadcast live on CooperCompanies' website, www.investor.coopercos.com , at approximately 5:00 PM ET. It will also be available for replay on CooperCompanies' website, www.investor.coopercos.com . Alternatively, you can dial in to the conference call at 800-715-9871; conference ID 2026064. About CooperCompanies CooperCompanies (Nasdaq: COO) is a leading global medical device company focused on improving lives one person at a time. The Company operates through two business units, CooperVision and CooperSurgical. CooperVision is a trusted leader in the contact lens industry, improving the vision of millions of people every day. CooperSurgical is a leading fertility and women's health company dedicated to assisting women, babies and families at the healthcare moments that matter most. Headquartered in San Ramon, CA, CooperCompanies ("Cooper") has a workforce of more than 16,000 with products sold in over 130 countries. For more information, please visit www.coopercos.com. Forward-Looking Statements This earnings release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Statements relating to guidance, plans, prospects, goals, strategies, future actions, events or performance and other statements of which are other than statements of historical fact, including our fiscal year 2025 financial guidance are forward looking. In addition, all statements regarding anticipated growth in our revenues, anticipated effects of any product recalls, anticipated market conditions, planned product launches, restructuring or business transition expectations, regulatory plans, and expected results of operations and integration of any acquisition are forward-looking. To identify these statements look for words like "believes," "outlook," "probable," "expects," "may," "will," "should," "could," "seeks," "intends," "plans," "estimates" or "anticipates" and similar words or phrases. Forward-looking statements necessarily depend on assumptions, data or methods that may be incorrect or imprecise and are subject to risks and uncertainties. Among the factors that could cause our actual results and future actions to differ materially from those described in forward-looking statements are: adverse changes in the global or regional general business, political and economic conditions including the impact of continuing uncertainty and instability of certain countries, man-made or natural disasters and pandemic conditions, that could adversely affect our global markets, and the potential adverse economic impact and related uncertainty caused by these items; the impact of international conflicts and the global response to international conflicts on the global and local economy, financial markets, energy markets, currency rates and our ability to supply product to, or through, affected countries; our substantial and expanding international operations and the challenges of managing an organization spread throughout multiple countries and complying with a variety of legal, compliance and regulatory requirements; foreign currency exchange rate and interest rate fluctuations including the risk of fluctuations in the value of foreign currencies or interest rates that would decrease our net sales and earnings; our existing and future variable rate indebtedness and associated interest expense is impacted by rate increases, which could adversely affect our financial health or limit our ability to borrow additional funds; changes in tax laws, examinations by tax authorities, and changes in our geographic composition of income; acquisition-related adverse effects including the failure to successfully achieve the anticipated net sales, margins and earnings benefits of acquisitions, integration delays or costs and the requirement to record significant adjustments to the preliminary fair value of assets acquired and liabilities assumed within the measurement period, required regulatory approvals for an acquisition not being obtained or being delayed or subject to conditions that are not anticipated, adverse impacts of changes to accounting controls and reporting procedures, contingent liabilities or indemnification obligations, increased leverage and lack of access to available financing (including financing for the acquisition or refinancing of debt owed by us on a timely basis and on reasonable terms); compliance costs and potential liability in connection with U.S. and foreign laws and health care regulations pertaining to privacy and security of personal information such as the Health Insurance Portability and Accountability Act of 1996 (HIPAA) and the California Consumer Privacy Act (CCPA) in the U.S. and the General Data Protection Regulation (GDPR) requirements in Europe, including but not limited to those resulting from data security breaches; a major disruption in the operations of our manufacturing, accounting and financial reporting, research and development, distribution facilities or raw material supply chain due to challenges associated with integration of acquisitions, man-made or natural disasters, pandemic conditions, cybersecurity incidents or other causes; a major disruption in the operations of our manufacturing, accounting and financial reporting, research and development or distribution facilities due to the failure to perform by third-party vendors, including cloud computing providers or other technological problems, including any related to our information systems maintenance, enhancements or new system deployments, integrations or upgrades; a successful cybersecurity attack which could interrupt or disrupt our information technology systems, or those of our third-party service providers, or cause the loss of confidential or protected data; market consolidation of large customers globally through mergers or acquisitions resulting in a larger proportion or concentration of our business being derived from fewer customers; disruptions in supplies of raw materials, particularly components used to manufacture our silicone hydrogel lenses; new U.S. and foreign government laws and regulations, and changes in existing laws, regulations and enforcement guidance, which affect areas of our operations including, but not limited to, those affecting the health care industry, including the contact lens industry specifically and the medical device or pharmaceutical industries generally, including but not limited to the EU Medical Devices Regulation (MDR), and the EU In Vitro Diagnostic Medical Devices Regulation (IVDR); legal costs, insurance expenses, settlement costs and the risk of an adverse decision, prohibitive injunction or settlement related to product liability, patent infringement, contractual disputes, or other litigation; limitations on sales following product introductions due to poor market acceptance; new competitors, product innovations or technologies, including but not limited to, technological advances by competitors, new products and patents attained by competitors, and competitors' expansion through acquisitions; reduced sales, loss of customers, reputational harm and costs and expenses, including from claims and litigation related to product recalls and warning letters; failure to receive, or delays in receiving, regulatory approvals or certifications for products; failure of our customers and end users to obtain adequate coverage and reimbursement from third-party payers for our products and services; the requirement to provide for a significant liability or to write off, or accelerate depreciation on, a significant asset, including goodwill, other intangible assets and idle manufacturing facilities and equipment; the success of our research and development activities and other start-up projects; dilution to earnings per share from acquisitions or issuing stock; impact and costs incurred from changes in accounting standards and policies; risks related to environmental laws and requirements applicable to our facilities, products or manufacturing processes, including evolving regulations regarding the use of hazardous substances or chemicals in our products; risks related to environmental, social and corporate governance (ESG) issues, including those related to regulatory and disclosure requirements, climate change and sustainability; and other events described in our Securities and Exchange Commission filings, including the “Business”, “Risk Factors” and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections in the Company’s Annual Report on Form 10-K for the fiscal year ended October 31, 2024, as such Risk Factors may be updated in annual and quarterly filings. We caution investors that forward-looking statements reflect our analysis only on their stated date. We disclaim any intent to update them except as required by law. Contact: Kim Duncan Vice President, Investor Relations and Risk Management 925-460-3663 ir@cooperco.com THE COOPER COMPANIES, INC. AND SUBSIDIARIES GAAP to Non-GAAP Reconciliation Constant Currency Revenue Growth and Organic Revenue Growth Net Sales
A closer look at Hunter Biden’s pardonISLAMABAD: Prime Minister Shehbaz Sharif has vowed to take decisive action against “future instances of violent protests and disruptive sit-ins.” He underscored that the government would no longer tolerate activities that jeopardise the nation’s economy and stability. Addressing the federal cabinet on Wednesday, the prime minister emphasised a zero-tolerance policy toward those inciting violence. While refraining from explicitly naming Pakistan Tehreek-e-Insaf (PTI), he implicitly criticised the party for orchestrating recent demonstrations in the federal capital, which caused widespread disruption. He insisted that such incidents necessitate a more stringent approach to prevent their recurrence. Sharif drew attention to the economic fallout as the protests took place. He spoke about how life in Islamabad and Rawalpindi was paralysed, leaving businesses shuttered and daily wage earners unable to make ends meet. “The turmoil disrupted supply chains, forced factory closures, and left patients in urgent need of medical care stranded due to blocked roads.” The prime minister also highlighted the broader economic ramifications, noting a sharp decline in the Pakistan Stock Exchange (PSE), which plummeted by 4,000 points in a single day after reaching a record high of 99,000 points. “These agitators have become adversaries of Pakistan’s progress,” he stated. “Their actions repeatedly derail our economy. Stability fosters business growth and investment, and we must safeguard these principles at all costs.” Sharif also condemned the PTI for disruptive tactics, which he described as a harmful precedent in Pakistan’s political history, citing the 2014 sit-in; a 126-day-long protest that delayed the visit of Chinese President Xi Jinping, stalling major projects under the China-Pakistan Economic Corridor (CPEC). He also referenced protests during key diplomatic events, such as the Shanghai Cooperation Organization (SCO) summit in Islamabad, which alarmed foreign dignitaries and tarnished Pakistan’s global image. Even Saudi officials, the prime minister noted, expressed concerns about the instability stemming from political agitation. “This culture of chaos and anarchy is unacceptable,” Sharif said. “No responsible political party in our history has ever stooped to such levels. The PTI’s actions have damaged our international relationships and economic stability, for the sake of personal interests.” The prime minister extended gratitude to law enforcement agencies, including the Islamabad, Punjab, and Sindh police, as well as the Rangers, for their effective handling of recent protests. He singled out the Chief of Army Staff for his crucial support in maintaining order. While affirming the constitutional right to peaceful protest, Shehbaz Sharif stressed that no one has the right to disrupt public life or destroy national assets. He lauded the coordinated efforts of law enforcement agencies in dispersing violent demonstrators, restoring calm, and safeguarding citizens. However, he criticised the provincial government in Khyber Pakhtunkhwa (KP) for neglecting its responsibilities. He accused the KP government of focusing on instigating violence in the federal capital rather than addressing rising insurgency and lawlessness in the province. “While the people of KP suffered from increasing insecurity, their government was busy orchestrating provocations against the federation,” he remarked. Sharif reiterated the need for exemplary punishment for individuals involved in violent incidents, including the May 9 riots. He argued that a lack of accountability emboldened perpetrators, leading to repeated disruptions. “If the culprits of the May 9 riots had faced appropriate punishment, we wouldn’t be witnessing this chaos today,” he said. “The cycle of unrest must end for Pakistan’s future.” Highlighting his government’s efforts to stabilise the economy, which he described as being on a path to recovery despite numerous challenges, Sharif credited the coalition government’s difficult yet necessary decisions for averting a potential default. “Inflation is easing, and we are seeing the fruits of bold, collaborative actions,” he noted, praising coalition partners for prioritising national interests over political considerations. “In the last eight months, we have made significant strides toward economic stabilisation. These achievements are the result of teamwork and determination, not miracles.” “It pains them to see the country stabilising and moving forward,” he added, alleging that the opposition was disheartened by Pakistan’s economic recovery. “It hurts them that Pakistan is stabilising and moving forward,” he said. The prime minister also criticised what he described as PTI’s self-serving political strategies, accusing its leadership of prioritising personal ambitions over national welfare. He claimed that the party’s actions had strained relations with friendly nations and tarnished Pakistan’s reputation. “This is not politics; it is chaos of the worst kind,” Sharif stated. “There is no place for such behavior in a civilised democracy.” He added that PTI’s leadership blatantly disregarded directives from the Islamabad High Court, undermining constitutional norms in their quest for power. In his concluding remarks, the prime minister declared his government’s commitment to ensuring such disruptions do not recur. He emphasised that the administration would take all necessary steps to uphold peace and stability, which are essential for Pakistan’s progress. “We will not allow the country’s stability to be jeopardised, not on our watch or anyone else’s,” he said. “The government’s priority is to focus on building a stronger, more resilient Pakistan, and we will take every step to safeguard this mission.” The prime minister assured the nation that his administration remains dedicated to fostering economic growth, strengthening international relations, and ensuring law and order. Save my name, email, and website in this browser for the next time I comment. Δ document.getElementById( "ak_js_1" ).setAttribute( "value", ( new Date() ).getTime() );
BOSTON (AP) — UConn coach Jim Mora pulled a move that would make Bill Belichick proud while preparing the Huskies to play the notoriously churlish former New England Patriot's next team in his old backyard. Mora and his players were more than 45 minutes late for what was scheduled as a 30-minute media availability a day before Saturday's Fenway Bowl against North Carolina. Mora then gave a non-apology straight out of Belichick’s playbook. “We practice at a certain time the day before a game,” Mora said. “And we stuck to the script.” A six-time Super Bowl winner in New England with Tom Brady, Belichick was fired after going 4-13 in 2023, leaving him just 14 wins short of matching Don Shula’s all-time record for NFL victories. Unable to land a pro job at the age of 72, Belichick signed on with North Carolina — his first college gig — when they fired 73-year-old Mack Brown. Belichick hasn’t taken over on the Tar Heels' sideline yet; interim coach Freddie Kitchens — another ex-Cleveland Browns coach — will lead them in the Fenway Bowl. But the future Hall of Famer's potential return to a football field in Boston has been the biggest story ahead of Saturday’s game. Belichick did not attend media day, and Fenway Bowl executive director Brett Miller tried to preempt questions about him by asking reporters “to keep questions focusing on the players and coaches out here today.” “I don’t need to beat around the bush any more than that,” he said in comments that would have been cryptic if it weren’t so obvious to everyone who he meant. “I know there’s probably a lot of questions that you guys have about next year, particularly one side. Please do your best to keep it to these guys, because they’ve earned the right to be here.” The request wasn’t completely successful, with Kitchens taking a question about Belichick specifically and saying he talks to his new boss every day. Earlier this month, Kitchens said: “He asks questions; I answer the questions.” “I’m going to try to soak in all I can from him, and be a better coach because of it,” Kitchens said after Belichick was hired. “I love Carolina, I want what’s best for Carolina, and I know that right now at this moment in time, coach Belichick is what’s best for Carolina. “At the end of the day, he’s a ballcoach,” he said, “and I enjoy working for ballcoaches.” Mora also brushed off a question about whether the next Carolina coach would have any impact on Saturday's game. “It's irrelevant to us," said Mora, who was 0-1 against Belichick in four seasons as an NFL head coach. "We can't control the emotions of our opponents. And as far as I know, coach Belichick will not be taking the football field on Saturday, so it's not relevant to this football team in our preparation. North Carolina (6-6) will be playing in a bowl for the sixth straight year – the second-longest streak in program history. The Tar Heels climbed from back-to-back nine-loss seasons in the final years of Larry Fedora to reach into The Associated Top 25 in each of the previous four seasons under Brown, who also coached them from 1988-97 in one of the most successful eras of Carolina football history. After starting out 3-0 this year, the Tar Heels lost four straight — including a 70-50 loss to Sun Belt Conference team James Madison. They won three more to gain bowl eligibility before a loss to Boston College that sealed Brown's fate, and a season-ending loss to rival NC State. UConn is playing in its second bowl game in three seasons under Jim Mora, bouncing back from last year’s 3-9 record to post its first eight-win season since Randy Edsall took the Huskies to the Fiesta Bowl in 2010. An independent, UConn won all of its games against the non-Power 4 conferences and lost to Syracuse, Wake Forest and Duke of the Atlantic Coast Conference and Maryland of the Big Ten. Miller said the bowl, which has struggled to find traction in a city more focused on the success of its professional sports teams, sold more tickets this year than in its first two. The Belichick angle is certainly part of that, but the game has also had some good success picking teams, hosting Louisville in 2022 -- the year before the Cardinals climbed into The Associated Press Top 10 – and then SMU last year, one season before the Mustangs made the College Football Playoff. “Could one of these teams be next,” Miller said. “We’ll see.” Get poll alerts and updates on the AP Top 25 throughout the season. Sign up here . AP college football: https://apnews.com/hub/ap-top-25-college-football-poll and https://apnews.com/hub/college-footballGitLab CFO Brian Robins sells $675,895 in stock
Game-changing holiday gifts for building fires, printing photos, watching birds and moreTrump Cabinet picks, appointees targeted by bomb threats and swatting attacks
CEO killer suspect: golden boy who soured on US health systemFinding the perfect gift can be daunting. The only way to truly ensure you get it right would be to ask the recipient what they want, but that wouldn’t be much fun for either of you. Luckily, there’s another tactic to help you earn a “gift whisperer” reputation: seeking out unique, practical, game-changing gifts that will truly surprise and delight. But that’s about as easy as it sounds, which is to say it’s not easy at all. So, we’ve done the legwork for you. Start making your list with this compilation of some of the most innovative, functional and fun gifts of 2024. There’s something for every budget. This image provided by FinaMill shows the FinaMill Ultimate Spice Grinder Set. The new FinaMill Ultimate Spice Grinder set elevates the pedestrian pepper and spice mill in both function and style. A pepper grinder, really? Bear with me: The new FinaMill Ultimate Spice Grinder set elevates the pedestrian pepper and spice mill in both function and style. Available in three colors (Sangria Red, Midnight Black and Soft Cream), the rechargeable-battery unit grinds with a light touch rather than hand-tiring twists. That’s easier for everyone and especially helpful for those experiencing hand or wrist issues such as arthritis, carpal tunnel syndrome or tendinitis. And it’s fun to use. The set includes a stackable storage tray and four pods that can be easily swapped as needed: The GT microplane grater for hard spices, nuts and chocolate; the MAX for large spices and dried herbs; the ProPlus for smaller and oily spices; and the Pepper Pod for, well, pepper. $110. This image provided by Pull Start Fire shows the matchless fire igniter in use. Made of 89% recycled materials, the food-safe, eco-friendly, 3-by-2-by-1-inch fire starters will light a fire quickly without matches, lighters or kindling. To build a fire Campers and backyard firepit lovers who have experienced the heartbreak of wet wood will appreciate having a three-pack of Pull Start Fire on hand. Made of 89% recycled materials, including sanding dust, wax and flint, the food-safe, eco-friendly, 3-by-2-by-1-inch fire starters will light a fire quickly without matches, lighters or kindling. Just loop the attached green string around a log, incorporate it into a wood stack, and pull the attached red string to ignite. Each windproof, rainproof block burns for 30 minutes. $29.99. This image provided by Souper Cubes shows No Mess Utensils held upright on pot edges. The No Mess Utensil lives up to its name. The utensils, a serving spoon and a ladle, have innovative, S-shaped handles designed to rest on the edge of a pot. The place for a ladle is on the pot The No Mess Utensil Set from Souper Cubes , a company known for its portioned, silicone freezer trays, lives up to its name. The utensils — a serving spoon and a ladle — have innovative, S-shaped handles designed to rest on the edge of a pot, keeping them upright so they won’t slip in. The design also eliminates the need for a spoon rest or, worse, placing dirty utensils on the kitchen counter or stovetop between stirs. A silicone coating in a choice of Aqua, Charcoal, Cranberry or Blueberry keeps handles cool to the touch. $24.99. This image provided by FeatherSnap shows a female cardinal bird perched on a FeatherSnap Wi-Fi Solar Powered Camera Smart Bird Feeder. Equipped with an HD camera, the dual-chamber feeder enables up-close livestreaming of avian visitors, as well as species-logging via the free mobile app. Up your birdwatching with this feeder The FeatherSnap Wi-Fi smart bird feeder could turn anyone into an avid birdwatcher. Equipped with an HD camera, the dual-chamber feeder enables up-close livestreaming of avian visitors, as well as species-logging via the free mobile app. An optional premium subscription ($59.99 annually or $6.99 monthly) includes unlimited photo and video storage, AI identification with species-specific details, and the opportunity to earn badges for logging new visitors. Turn on notifications to get alerts sent to your phone whenever there’s activity at the feeder. $179.99. This image provided by FUJIFILM North America Corporation and FUJIFILM Corporation Tokyo shows a smartphone printer. Fujifilm Instax's Mini Link 3 smartphone printer offers a touch of nostalgia without sacrificing technology. Just load the printer with film and connect it to your Android or iOS device via Bluetooth to print wallet-size photos. Printing old-fashioned photos via Bluetooth Fujifilm's Instax Mini Link 3 smartphone printer offers a touch of nostalgia without sacrificing technology. Just load the 4.9-by-3.5-by-1.3-inch printer with Instax Mini instant film and connect it to your Android or iOS device via Bluetooth to print wallet-size photos. If you want to get fancy, you can adjust brightness, contrast and saturation, or apply filters, including 3D augmented-reality effects, via the free Instax Mini Link app. It can also make collages of up to six images, or animate photos to share on social media. Available in Rose Pink, Clay White and Sage Green. $99.95. This image provided by easyplant shows a Marxii Calathea plant in a small, beige, self-watering pot. The appropriately named easyplant is one of the best gifts you can give your houseplant-loving friends, regardless of their experience level. Houseplants don't get much easier than this The appropriately named easyplant is one of the best gifts you can give your houseplant-loving friends, regardless of their experience level. Select a pot color, size and plant (or get recommendations based on sunlight requirements, pet friendliness and other attributes) and fill the self-watering container’s built-in reservoir roughly once a month. Moisture will permeate the soil from the bottom as needed, eliminating the often-fatal consequences of over- or under-watering. It’s also a literal lifesaver come vacation time. $49-$259. This image provided by Nama shows the M1 plant-based milk maker. If you've got a no-dairy friend on your list, a plant-based milk maker could save them money while allowing them to avoid unnecessary ingredients like sugar, stabilizers, thickeners and preservatives. Making your own (plant-based) milk If you’ve got a no-dairy friend on your list, a plant-based milk maker could save them money while allowing them to avoid sugar, stabilizers, thickeners and preservatives. The Nama M1 appliance both blends and strains ingredients, converting nuts, seeds, grains or oats into velvety-smooth milk in just one minute, with zero grit. And for zero waste, the pasty leftover pulp can be used in other recipes for added nutrients. The device also makes infused oils, flavored waters and soups. And, importantly, cleanup is easy. Available in white and black. $400. This image provided by QelviQ shows a wine bottle chiller. For friends who prefer stronger beverages, the QelviQ personal sommelier uses "smart" technology to ensure wine is served at its ideal temperature. The perfect temperature for 350,000-plus wines For friends who prefer stronger beverages, the QelviQ personal sommelier uses “smart” technology to ensure wine is served at its ideal temperature. Unlike traditional wine refrigerators, this device doesn’t take up any floor space. It also doesn’t chill wine to just one or two temperatures based on its color. Instead — paired with the free QelviQ app — the tabletop chiller relies on a database of more than 350,000 wines to bring a bottle to its specific recommended serving temperature in as little as 20 minutes. It also suggests food-wine and wine-food pairings. Plus, the appliance serves as a great icebreaker to inspire dinnertime conversation. Available in Exciting Red, Dashing Black and Dreamy White. $495. Casting light on the grill after dark This image provided by Uncommon Goods shows a 2-piece LED Grilling Tool Set. Uncommon Good's 2-piece LED Grilling Tool Set puts illumination into the handles of its stainless-steel spatula and tongs. Grilling food after dark — and ascertaining its doneness — can prove challenging without outdoor lighting, and it’s nearly impossible to cook while holding a flashlight. But as is often the case, the simplest of solutions can make the biggest of impacts: Uncommon Good’s 2-piece LED Grilling Tool Set puts illumination into the handles of its stainless-steel spatula and tongs. After use, the lights can be removed and the utensils run through the dishwasher. $40. Copyright 2024 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission. Make your house a home